Bachem Holding AG stock (CH0012530207): peptide specialist in the spotlight after Q1 2026 update

Bachem Holding AG has reported its Q1 2026 trading update and reiterated its outlook for the year, keeping the peptide specialist on the radar of healthcare and biotech investors.

Bachem Holding AG has attracted fresh attention from investors after publishing a trading update for the first quarter of 2026 and confirming its full-year guidance, according to a company release dated 04/24/2026 on the SIX Swiss Exchange news platform, as reported by SIX Exchange as of 04/24/2026. The peptide and oligonucleotide manufacturer highlighted ongoing demand in its core markets while maintaining its expectations for revenue growth and profitability in 2026, which keeps the stock in focus for healthcare-oriented portfolios, according to Bachem investor relations as of 04/24/2026.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Pharmaceuticals, biotech manufacturing (peptides and oligonucleotides)
• Headquarters/country: Bubendorf, Switzerland
• Core markets: Custom and generic peptide APIs for pharma and biotech customers worldwide
• Key revenue drivers: Contract manufacturing of peptide and oligonucleotide active pharmaceutical ingredients and related services
• Home exchange/listing venue: SIX Swiss Exchange (ticker: BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem Holding AG is a Swiss-based specialist in the development and manufacturing of peptides and oligonucleotides for the pharmaceutical and biotechnology industries. The company focuses on active pharmaceutical ingredients and related services used in research, clinical development and commercial drugs, according to Bachem company information as of 03/2026. Its business model centers on long-term supply relationships with drug developers that rely on high-quality, large-scale peptide production.

The group operates a network of manufacturing sites and laboratories in Europe, North America and Asia, providing both custom synthesis and catalog products to its customers, as described by Bachem locations overview as of 03/2026. Bachem serves pharmaceutical companies that use peptides as active ingredients in therapies for metabolic, oncological and other indications, as well as biotech firms and research organizations that require complex peptide and oligonucleotide molecules.

In addition to manufacturing, Bachem offers chemistry expertise, process development and scale-up support, which can be critical when customers move from preclinical research into clinical trials and commercial production. This integrated offering is designed to help clients manage regulatory requirements and quality standards associated with active pharmaceutical ingredients, according to Bachem services information as of 03/2026. The company positions itself as a partner across the full life cycle of peptide and oligonucleotide-based medicines.

Main revenue and product drivers for Bachem Holding AG

Bachem’s revenue is primarily generated from its active pharmaceutical ingredient (API) business, where it manufactures peptide and oligonucleotide compounds under contract for pharmaceutical and biotech customers. The company divides its activities into segments serving commercial APIs, clinical development projects and research-grade products, as described in its annual report for 2024 published on 03/14/2025 by Bachem annual report 2024 as of 03/14/2025. Commercial supply contracts can run for many years, providing recurring revenue when customer drugs reach the market.

The company also earns income from development services, where it supports customers in optimizing synthesis routes, improving yields and preparing for regulatory submissions. These projects can be important for winning future large-scale manufacturing mandates, according to the same annual report for 2024 published on 03/14/2025 by Bachem annual report 2024 as of 03/14/2025. As more peptide and oligonucleotide-based drugs move through clinical pipelines, the company sees opportunities to expand its share of commercial supply agreements.

Another revenue pillar is the catalog business, where Bachem sells standardized peptides and related products for research and diagnostic uses. While typically smaller in scale than commercial supply contracts, catalog sales can diversify the revenue base and help attract new customers. The group has emphasized investments in capacity expansion and technology, particularly for large-scale solid-phase peptide synthesis and emerging oligonucleotide manufacturing, as highlighted in its capital expenditure plans for 2024 and 2025 in the report published on 03/14/2025 by Bachem annual report 2024 as of 03/14/2025.

Conclusion

Bachem Holding AG remains a specialized player in the growing field of peptide and oligonucleotide manufacturing, with a business model built on long-term supply relationships and technical expertise. The recent Q1 2026 trading update and reiterated guidance underline management’s confidence in the current year, according to SIX Exchange as of 04/24/2026. For US investors following global healthcare supply chains, the stock offers exposure to a European contract manufacturer that serves international pharma and biotech customers, but as with all equities, performance will depend on execution, pipeline progression at client companies and broader market conditions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.